… Our results therefore suggest a lower risk of CNS progression in patients with somatic
EGFR mutations initially treated with gefitinib or erlotinib for advanced NSCLC than published …

… type EGFR and patients with EGFR mutations respectively. In either groups of wild-type EGFR
or mutant EGFR, gefitinib and erlotinib did … Erlotinib and gefitinib treatments do not result in …

… sensitivity to TKIs and correlated responses to gefitinib or erlotinib with the presence of
somatic mutations clustered in exons 18 to 21, which encode the tyrosine kinase domain of …

… (T790M) that blocks the capacity for gefitinib or erlotinib to inhibit EGFR, and amplification
of MET, which activates similar downstream signaling pathways, obviating the actions of …

… activation loop of the EGFR catalytic domain, one … mutation found in gefitinib and erlotinib
responders in lung cancer [1]. Similar mutations, ie missense mutations clustered in the EGFR …

… Most somatic EGFR mutations in NSCLCs have been reported to be heterozygous. However,
in the analysis of two of seven tumors (G1 and G3), no wild-type sequence was detected in …

… To detect EGFR mutations in a large background of wild-type EGFR genes derived from …
to each mutation were developed to cover more than 95% of the EGFR mutations previously …

… patients with 3381 somatic EGFR mutations. The majority of mutations have been reported
… lung cancer OR NSCLC OR erlotinib OR iressa OR tarceva) AND (mutation OR gefitinib OR …

… inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function
mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). …

… EGFR mutations are associated with sensitivity to the EGFR tyrosine kinase inhibitors gefitinib
and erlotinib… respond to treatment with gefitinib or erlotinib develop resistance to these …